Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents.

Poon M, Zeng L, Zhang L, Hsiao J, Wong E, Lam H, Bedard G, Chow E.

J Comp Eff Res. 2013 Jan;2(1):69-76. doi: 10.2217/cer.12.69. Review.

PMID:
24236523
[PubMed - indexed for MEDLINE]
2.

Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.

Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, Bedard G, Lao N, Chow R, Chow E.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):435-44. doi: 10.1016/j.clon.2013.03.003. Epub 2013 Apr 10. Review.

PMID:
23582277
[PubMed - indexed for MEDLINE]
3.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;5:CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
[PubMed - indexed for MEDLINE]
4.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
[PubMed - indexed for MEDLINE]
5.

Bisphosphonates in multiple myeloma.

Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.

Cochrane Database Syst Rev. 2002;(3):CD003188. Review. Update in: Cochrane Database Syst Rev. 2010;(3):CD003188.

PMID:
12137679
[PubMed - indexed for MEDLINE]
6.

Bisphosphonates in multiple myeloma.

Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A.

Cochrane Database Syst Rev. 2001;(4):CD003188. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD003188.

PMID:
11687178
[PubMed - indexed for MEDLINE]
7.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
[PubMed - indexed for MEDLINE]
8.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
[PubMed - indexed for MEDLINE]
9.

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.

Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE.

Leukemia. 2010 May;24(5):1043-9. doi: 10.1038/leu.2010.62. Epub 2010 Apr 8.

PMID:
20376081
[PubMed - indexed for MEDLINE]
10.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.

Clin Cancer Res. 2003 Jul;9(7):2394-9.

PMID:
12855610
[PubMed - indexed for MEDLINE]
Free Article
11.

Bisphosphonates in multiple myeloma.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD003188. doi: 10.1002/14651858.CD003188.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD003188.

PMID:
20238320
[PubMed - indexed for MEDLINE]
12.

Bisphosphonates for osteoporosis in primary biliary cirrhosis.

Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009144. doi: 10.1002/14651858.CD009144.pub2. Review.

PMID:
22161446
[PubMed - indexed for MEDLINE]
13.

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Lancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21.

PMID:
21771568
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Bisphosphonates for advanced prostate cancer.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006250. Review.

PMID:
17054286
[PubMed - indexed for MEDLINE]
15.

Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

Machado M, Cruz LS, Tannus G, Fonseca M.

Clin Ther. 2009 May;31(5):962-79. doi: 10.1016/j.clinthera.2009.05.009. Review.

PMID:
19539097
[PubMed - indexed for MEDLINE]
16.

Therapeutic options in the management of myeloma bone disease.

Berenson JR.

Semin Oncol. 2010 Jun;37 Suppl 1:S20-9. doi: 10.1053/j.seminoncol.2010.06.009. Review.

PMID:
20682368
[PubMed - indexed for MEDLINE]
17.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
[PubMed - indexed for MEDLINE]
18.

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, GarcĂ­a-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.

J Clin Oncol. 2013 Jun 20;31(18):2347-57. doi: 10.1200/JCO.2012.47.7901. Epub 2013 May 20.

PMID:
23690408
[PubMed - indexed for MEDLINE]
19.

Adverse events across generations of bone-modifying agents in patients with solid tumor cancers reported in Phase III randomized trials.

Poon M, Zhang L, Mok F, Li K, Emmenegger U, Wong E, Zhou M, Lam H, Lao N, Chow E.

J Comp Eff Res. 2013 Jan;2(1):77-91. doi: 10.2217/cer.12.72. Review.

PMID:
24236524
[PubMed - indexed for MEDLINE]
20.

Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.

Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):326-35. doi: 10.1016/j.clml.2011.04.004. Epub 2011 May 6.

PMID:
21700528
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk